New mutations found in common lung cancer subtype

the ONA take:

In a new study, published online in the journal Nature, researchers Identified novel mutations in an established cancer pathway in lung adenocarcinoma, the most common form of lung cancer. The researchers, who are affiliated with the The Cancer Genome Atlas (TCGA) Research Network, examined some 230 lung adenocarcinoma samples and reviewed their genomes, RNA, and proteins. In approximately 75 percent of the samples, the researchers identified mutations that were accelerating the RTK/RAS/RAF pathway. When mutations change the operation of the RTK/RAS/RAF pathway, signals that promote cancer cell proliferation run continuously. Gene mutations were discovered that would up RTK/RAS/RAF pathway activity in some 62 percent of the samples examined. The study authors also examined DNA copy number changes, and thereby discovered amplification in two oncogenes, ERBB2 and MET, located in the RTK/RAS/RAF pathway. Amplification of this sort can cause increased expression of encoded cell protein.




Identification of these novel mutations will help increase the number of possible therapeutic targets for this form of lung cancer, using existing drugs that have already proved effective in addressing these mutations. Previous TCGA analysis of squamous cell carcinoma (less common than lung adenocarcinoma) was conducted by TCGA Research Network scientists in 2012.

New mutations found in common lung cancer subtype
New mutations found in common lung cancer subtype
Researchers from The Cancer Genome Atlas (TCGA) Research Network have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer. Knowledge of these genomic changes may expand the number of possible therapeutic targets for this disease and potentially identify a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist.
READ FULL ARTICLE From Biosciencetechnology
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs